Pluristem Phase III hip fracture study misses primary endpoint but meets key secondary muscle strength measure

Pluri Inc.

Primary endpoint SPPB at week 26 not met; PLX-PAD showed no significant improvement vs placebo.
Hip Abduction Strength (HAS) significantly improved: injured leg +2kg at wk26 (p=0.047) and +4kg at wk52 (p=0.0022).
Uninjured leg also benefited: +1.8kg at wk26 (p=0.073) and +4kg at wk52 (p=0.0046) vs placebo.
6-minute walk test at wk52: PLX-PAD patients walked 296m vs 266m for placebo (positive trend).
Company plans to seek regulatory advice and explore partnerships to advance PLX-PAD development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.